标题:Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy
作者:Wang X.; Lang S.; Tian Y.; Zhang J.; Yan X.; Fang Z.; Weng J.; Lu N.;等 更多
作者机构:[Wang, X] Department of Biomaterials, College of Materials, Xiamen University, Xiamen, 361005, China;[ Lang, S] Depts. of Chem. and Biomed. Engineerin 更多
通讯作者:Li, Z(lizhu@nkdbio.com)
通讯作者地址:[Li, Z] Xiamen Nuokangde Biological Technology Co., Ltd.China;
来源:ACS Applied Materials and Interfaces
出版年:2020
DOI:10.1021/acscentsci.9b00956
摘要:Adoptive transfer of immune cells is being actively pursued for cancer treatment. Natural killer (NK) cells, a class of cytotoxic immune cells, generally lack inherent selectivities toward cancer. To bestow tumor-targeting abilities and enhance anticancer efficacy, a new strategy is established to glycoengineer NK cells. Carbohydrate-based ligands for CD22, a marker for B cell lymphoma, are introduced onto NK cells through either metabolic engineering or glyco-polymer insertion. Such NK cells exhibited greatly enhanced cytotoxicities toward CD22+ lymphoma cells in a CD22-dependent manner. Importantly, both CD22+ lymphoma cell lines and primary lymphoma cells from human cancer patients can be effectively killed by the engineered NK cells. Furthermore, glycoengineered NK cells provided significant protection to tumor-bearing mice. Thus, NK cell glycoengineering is an exciting new approach for cancer treatment complementing the current immune cell genetic engineering strategy. Copyright © 2020 American Chemical Society.
收录类别:SCOPUS
Scopus被引频次:3
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081643804&doi=10.1021%2facscentsci.9b00956&partnerID=40&md5=a7486675ce384122fae5a4a222ed6288
TOP